Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

Disclosed are compounds of following formula (I): ##STR00001##
in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.

Compositions and methods for treating glioma and converting glioma cells into neurons are provided. The compositions contain an effective amount of SKL2001, and may also contain one, two, three or four of 0431542, LDN193189, CHIR99021, and DAPT. Pharmaceutical compositions containing SKL2001 and one, two, three or four of SB431542, LDN193189, CHIR99021, and DAPT are provided. Also provided are articles of manufacture which contain one or more sealed containers that contain SKL2001 and one, two, three or four of SB431542, LDN193189, CHIR99021, and DAPT, are provided. The articles of manufacture can contain printed material providing an indication that the compound(s) are for use in treating glioma.

Compositions and methods for treating glioma and converting glioma cells into neurons are provided. The compositions contain an effective amount of SKL2001, and may also contain one, two, three or four of 0431542, LDN193189, CHIR99021, and DAPT. Pharmaceutical compositions containing SKL2001 and one, two, three or four of SB431542, LDN193189, CHIR99021, and DAPT are provided. Also provided are articles of manufacture which contain one or more sealed containers that contain SKL2001 and one, two, three or four of SB431542, LDN193189, CHIR99021, and DAPT, are provided. The articles of manufacture can contain printed material providing an indication that the compound(s) are for use in treating glioma.

This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).

The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).

The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

##STR00001##